Who will fund hypothesis testing studies?

doi:10.1136/bmj.332.7542.666-c

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Mira Harrison-Woolrych, director (Mira.harrison-woolrych@stonebow.otago.ac.nz)

Intensive Medicines Monitoring Programme, University of Otago, Dunedin, New Zealand

EDITOR—Although Loke et al concluded that case reports in pharmacovigilance have limited value,1 case reports or series are valuable as hypothesis generating papers, which benefit clinicians and patients. The number of follow-up studies is only one outcome by which to judge the value of case reports or series, but other outcomes may be more difficult to study.

Although case …